<i>trans</i>-Directing Ability of the Amide Group: Enabling the Enantiocontrol in the Synthesis of 1,1-Dicarboxy Cyclopropanes. Reaction Development, Scope, and Synthetic Applications
作者:David Marcoux、Sébastien R. Goudreau、André B. Charette
DOI:10.1021/jo902066y
日期:2009.12.4
enantioselective formation of 1,1-cyclopropane diesters via the metal-catalyzed cyclopropanation of olefins. The strategies envisioned to achieve such a goal are discussed as well as the results that led us to the discovery of the powerful trans-directingability of the amidegroup in Rh(II)-catalyzed cyclopropanation reactions. We show how this feature enables a solution for the stereoselective synthesis
Direct Carboxylation of the Diazo Group <i>ipso</i>-C(sp<sup>2</sup>)–H bond with Carbon Dioxide: Access to Unsymmetrical Diazomalonates and Derivatives
作者:Qianyi Liu、Man Li、Rui Xiong、Fanyang Mo
DOI:10.1021/acs.orglett.7b03573
日期:2017.12.15
The directcarboxylation of the ipso-C(sp2)–H bond of a diazo compound with carbondioxide under mild reaction conditions is described. This method is transition-metal-free, uses a weak base, and proceeds at ambient temperature under atmospheric pressure in carbondioxide. The carboxylation exhibits high reactivity and is amenable to subsequent diversification. A series of unsymmetrical 1,3-diester/keto/amide
Ectonucleotidase inhibitors and methods of use thereof
申请人:Calithera Biosciences, Inc.
公开号:US11078228B2
公开(公告)日:2021-08-03
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
本发明涉及新型杂环化合物及其药物制剂。本发明还涉及使用本发明的新型杂环化合物治疗或预防癌症的方法。
10.1021/acs.orglett.4c02402
作者:Patel, Shivani、Greenwood, Nathaniel S.、Mercado, Brandon Q.、Ellman, Jonathan A.
DOI:10.1021/acs.orglett.4c02402
日期:——
The Rh(II)-catalyzed enantioselective S-alkylation of sulfenamides with α-amide diazoacetates at 1 mol % catalyst loading to obtain sulfilimines in high yields and enantiomeric ratios of up to 99:1 is reported. The enantioenriched sulfilimine products incorporate versatile amide functionality poised for further elaboration to diverse sulfoximines with multiple stereogenic centers, including by highly